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Abstract
Understanding the mechanisms of chromosomal double-strand break repair (DSBR) provides insight into genome instability,
oncogenesis and genome engineering, including disease gene correction. Research into DSBR exploits rare-cutting
endonucleases to cleave exogenous reporter constructs integrated into the genome. Multiple reporter constructs have been
developed to detect various DSBR pathways. Here, using a single endogenous reporter gene, the X-chromosomal disease gene
encoding hypoxanthine phosphoribosyltransferase (HPRT), we monitor the relative utilization of three DSBR pathways
following cleavage by I-SceI or CRISPR/Cas9 nucleases. For I-SceI, our estimated frequencies of accurate or mutagenic non-
homologous end-joining and gene correction by homologous recombination are 4.1, 1.5 and 0.16%, respectively. Unexpectedly,
I-SceI and Cas9 induced markedly different DSBR profiles. Also, using an I-SceI-sensitive HPRT minigene, we show that gene
correction is more efficient when using long double-stranded DNA than single- or double-stranded oligonucleotides. Finally,
using both endogenous HPRT and exogenous reporters, we validate novel cell cycle phase-specific I-SceI derivatives for
investigating cell cycle variations in DSBR. The results obtained using these novel approaches provide new insights into
template design for gene correction and the relationships between multiple DSBR pathways at a single endogenous disease
gene.
Introduction
Inappropriate repair of chromosomal DNA double-strand breaks
(DSBs) can lead to mutagenesis, gross chromosomal instability
and genetic disease (1). Knowledge of DSB repair pathways, and
their defects in particular cancers, has helped to define oncogenic
mechanisms and to develop new therapeutic strategies (2). Such
knowledge also underpins powerful genome engineeringmethods
that use customized endonucleases, including clustered regulatory
interspaced short palindromic repeat (CRISPR)/Cas-based RNA-
guided nucleases, to make targeted chromosomal DSBs (3). Thera-
peutic gene targeting (GT) (4) for the correction of disease-causing
mutations is an emerging application of such methods (5).
There are two main DSB repair (DSBR) mechanisms: homolo-
gous recombination (HR) (6) and non-homologous end-joining
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(NHEJ) (7). HR requires a homologousDNA repair template, usually
in the form of a sister chromatid, which ensures that the original
DNA sequence is restored. Repair templates can be engineered,
however, and introduced into cells to make a defined genomic
modification via HR (GT). HR requires extensive 5′–3′ end-resec-
tion at DSBs to generate single-stranded tails that form a RAD51
nucleofilament capable of invading a duplex DNA template. Re-
quirements for a sister chromatid template and cyclin-depend-
ent kinase activity (8) restrict HR to the S and G2 phases of the
cell cycle (9). NHEJ lacks these requirements and can occur
throughout the cell cycle. In classical NHEJ, DNA ends are pro-
tected by the Ku heterodimer; this minimizes end-resection al-
lowing for accurate end-joining (accNHEJ, also termed precise
ligation) (7,10). Here, we use the term accNHEJ to describe the
joining of any two DNA ends that have undergone no gain or
loss of nucleotides. In some circumstances, such as the absence
of Ku heterodimer, NHEJ is more likely to involve limited end-
resection, resulting in insertions and/or deletions (indels) at the
site of the DSB. Such mutagenic NHEJ (mutNHEJ) often involves
the annealing of short (e.g. 2–6 nt) sequence homologies from
each side of the DSB (micro-homology-mediated end-joining;
MMEJ). In an analogous pathway termed single-strand annealing
(SSA), that can also be considered a form of non-conservative
RAD51-independent HR, deletions result from extensive end-re-
section followed by annealing of longer (e.g. >100 nt) repeats (6).
Customized endonucleases can be introduced into cells to
generate targeted indels via mutNHEJ or to promote specific
modifications via GT. An ability to promote one DSBR pathway
at the expense of others would be valuable for facilitating the de-
sired genome engineering outcome. DNA resection, cell cycle
phase, DNA end-structure and host cell type are all known to in-
fluence DSBR pathway choice (11,12). Further investigations into
how these and other variables affect pathway choice will be im-
portant to facilitate genome manipulation and improve our un-
derstanding of DSBR and genome instability.
Research into DSBR has benefitted greatly from assays for the
repair of defined chromosomal DSBs generated by rare-cutting en-
donucleases. Typically, a homing endonuclease, such as I-SceI, is
used to cleave an exogenous reporter construct that has been ran-
domly inserted into the genome. Many such constructs have been
developed using reporters that fluoresce or confer drug resistance.
Most are designed to detect, without recourse to structural ana-
lyses of the repaired locus, a single type of DSBR, including intra-
chromosomal HR (13,14), GT (15), SSA (16), mutNHEJ or accNHEJ
(10,17–20) and MMEJ (21) (reviewed in 22). Simultaneous reporting
for multiple DSBR pathways can be achieved by integrating mul-
tiple constructs intoa single clone (20,23,24) or by integratinga sin-
gle reporter construct that detects multiple types of repair (25,26).
DSBR mechanisms are known to be affected by chromoso-
mal location (27–31) and by epigenetic factors (32–34) that are
in turn affected by exogenous DNA sequences (35–37). It is, there-
fore, important to minimize or eliminate these variables when
comparing different exogenous DSBR reporters. Differences in
chromosomal location have been avoided by integrating different
constructs at the same locus (16) ormitigated by averaging the be-
haviour of constructs at multiple integration sites (23). These pre-
cautions are rarely taken, however, and do not control for any
differences between constructs in their effects on the host gen-
ome. For these reasons, single reporters that can detect multiple
types of DSBR at a single locus are highly desirable. To date, the
only reporters that achieve this without the need to sequence
breakpoints are traffic light reporter (TLR) systems that elegantly
combine multiple fluorescent marker genes to detect mutNHEJ
and GT (25) or mutNHEJ, GT and SSA (26).
In the present study, we use an endogenous gene as a reporter
to detect three types of nuclease-induced DSBR: mutNHEJ, GT
and accNHEJ. Our reporter is the highly conserved X-chromo-
somal gene encoding hypoxanthine phosphoribosyltransferase
(HPRT), an enzyme that is essential for the salvage pathway of
purine biosynthesis, and deficiencies of which cause a range of
clinical phenotypes, including Lesch Nyan disease (38). We
choseHPRT not only because it is amodel disease gene, naturally
residing and expressed in growing cells, but also because it is
drug selectable. Thus, cells with inactive or active HPRT alleles
can be selected, respectively, in medium containing 6-thiogua-
nine (6TG) or hypoxanthine, aminopterin and thymidine (HAT).
Although HPRT has to be used extensively for studies of random
mutagenesis and un-induced GT (39–43), it has not been system-
atically exploited for monitoring nuclease-induced DSBR. Here,
we cleave HPRT alleles with I-SceI or Cas9 nuclease and estimate
the relative frequency of three different DSBR outcomes. We also
use an I-SceI-sensitive HPRT minigene to investigate how the fre-
quency of gene correction is influenced by repair template
design. As an additional tool, to facilitate studies of cell cycle con-
trol of DSBR, we describe novel I-SceI derivatives that are ex-
pressed in a cell cycle-dependent fashion.
Results
Silent introduction of an I-SceI site into a mouse HPRT
minigene
The I-SceI recognition sequence (ATTACCCTGTTATCCCTA) trans-
lates into an amino-acid sequence (ITLLSL) with only one differ-
ence to a sequence (QTLLSL) in the normal HPRT enzyme.
Assuming this change (Q144I) does not disrupt HPRT function,
we introduced the I-SceI site into the exon-6-derived region of a
mouse HPRT minigene (mHPRT) to generate mHP-I-RT (Fig. 1). As
a control, we introduced a stop codon (*) immediately down-
stream of the I-SceI site, to generatemHP-I*-RT. When transfected
into human HPRT− human fibrosarcoma (HT1080) cells, mHPRT
and mHP-I-RT conferred resistance to HAT medium (HATR)
Figure 1. Mouse HPRT minigenes used in this study. Numbered black boxes
represent exons. The mouse minigene is driven by the PGK promoter (grey box)
and all but the last two introns are removed. Partial nucleotide, and amino-
acid, sequences from exon 6 are shown for the wild-type (WT) allele and for
alleles modified to carry an I-SceI site (boxed) with (mHP-I*-RT) or without (mHP-
I-RT) an adjacent stop codon. Altered residues are shown in bold.
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equallywell, whereasmHP-I*-RT conferredno resistance (Table 1).
This indicates that the Q145I mutation has little or no effect on
HPRT function, which is consistent with structural and evolu-
tionary considerations (Supplementary Material, Fig. S1).
I-SceI-induced correction and mutagenesis of a mouse
HPRT minigene
To study I-SceI-induced gene correction by HR, the mHP-I*-RT
minigenewas stably integrated into anHPRT− cell line (HTtetSCE;
Supplementary Material, Table S1) carrying a tetracycline-regu-
lated I-SceI gene. One of the resulting clones with a single copy
ofmHP-I*-RT (clonem2.1) grewnormallywith orwithout tetracyc-
line. Using this clone, we examined the efficiency ofmHPRT gene
correction by various templates: single- or double-stranded
oligonucleotides or long double-stranded DNA (Fig. 2A). Each
template had the wild-type sequence, an I-SceI site, or an I-SceI
site and adjacent stop codon. Gene correction data are summar-
ized (Fig. 2B) for oligonucleotide templates (left panel) and long
templates (right panel). As expected, only templates without
the stop codon gave rise to HATR colonies. Consistent with previ-
ous studies (15,44,45), correction by all repair templates was
greatly stimulated by I-SceI (up to 800-fold). We alsomade the fol-
lowing observations (see Discussion for interpretations). First,
sense and antisense oligonucleotides supported gene correction
equally well. Second, single-stranded oligonucleotides were
more effective than double-stranded oligonucleotides. Third, un-
like correction with single-stranded templates, where increasing
the homology length above 40 nt had little impact (46), increasing
the homology length of double-stranded templates from 60 bp to
Figure 2. I-SceI-induced correction (A andB) ormutagenesis (C) of an integratedmHPRTminigene. (A) Gene correction templates are shown schematically, alignedwith the
target mHP-I*-RT minigene. Templates were sense or antisense single-stranded oligonucleotides (SssO, AssO), dsOs or dsL (for oligonucleotide sequences, see
Supplementary Material, Table S3). Each of these four template classes was made with the I-SceI site and stop codon (-I*), the I-SceI site only (-I) or neither (-wt; wild-type).
(B) HPRT − cells (clone 2.1) carrying the mHP-I*-RT minigene and a tetracycline-regulated I-SceI expression cassette were grown with or without tetracycline and transfected
with the indicated templates detailed in (A). The frequencies of resulting HAT-resistant colonies are shown for oligonucleotides templates (left panel) and dsL templates
(right panel). Error bars show SDs for three experiments. (C) Three HPRT+ clones (14.2, 7.1 and 5.1) carrying themHP-I-RTminigenewere transfected with I-SceI expression
plasmid (+), or a vector control (−), and selected in 6TG. Colonies resulting from selection of 5 × 105 cells are shown.
Table 1. Rescue of HPRT− cells with mHP-I-RT
Transfected plasmid Encoded minigene Experiment 1a Experiment 2 Experiment 3
pBT/PGK-HPRT (R1) mHPRT (wt) 189 241 266
pBT/PGK-HP-I-RT (R1) mHP-I-RT 198 213 259
pBT/PGK-HP-I*-RT (R1) mHP-I*-RT 0 0 0
aIn each experiment, plasmids expressing the indicatedminigenewere individually electroporated into 1 millionHPRT− cells whichwere then selected in HATmedium to
generate the indicated numbers of HATR colonies.
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1.7 kb resulted in a 21- to 26-fold increase in gene correction
[Fig. 2B; compare double-stranded oligonucleotide (dsO) and
long double-stranded DNA (dsL)]. Fourth, despite having eight
additional mismatches to the target, wild-type repair templates
were always more effective than their equivalent templates
with I-SceI sites. Finally, correction by long double-stranded tem-
plates was 9- to 26-fold more efficient than by oligonucleotides.
We next attempted to measure DSB-induced loss of HPRT
function using clones with integrated mHP-I-RT minigenes.
Three such HATR clones (14.2, 7.1 and 5.1; Supplementary Mater-
ial, Table S1) were transiently transfected with I-SceI expression
plasmid (pCMV3xnls-I-SceI) and selected in 6TG. For each clone,
I-SceI expression clearly increased the frequency of 6TG-resistant
(6TGR) colonies (Fig. 2C), but frequencies varied greatly between
clones. Such variations, as well as the appreciable frequencies
of spontaneous 6TGR colonies, are most likely result of chromo-
somal position effects.
Strategy for generating an I-SceI-sensitive human HPRT+
allele
To avoid chromosomal position effects and establish a standard
endogenous locus for analysing DSBR, we generated I-SceI-sensi-
tive human HPRT alleles. The structure of the endogenous HPRT
gene and I-SceI-sensitive derivatives is shown in Figure 3A. Our
strategy for generating these and using them for accNHEJ and
mutNHEJ assays is outlined in Figure 3B. First, a targeting construct
(pLB-puro) was used to introduce a puromycin-resistance cassette
into exon 6 (Fig. 3Ba). This cassette was flanked by I-SceI sites, al-
lowing it to be excised by I-SceI. If excision is followed by accNHEJ
of the two resulting chromosome ends, a functional HPRT allele
carrying an I-SceI site in exon 6 is generated (Fig. 3Bb). The fre-
quency of HATR colonies formed in this step, therefore, provides
a measure of I-SceI-induced accNHEJ. (Like other accNHEJ reporter
assays (10,17–20), this scheme involves the deletion of DNA be-
tween two I-SceI sites, butmeasures accNHEJ rather thanmutNHEJ
because the joined ends suffer no gain or loss of nucleotides.) Fi-
nally, the resulting HATR colonies can then be used to generate
6TGR colonies as a measure of I-SceI-induced mutNHEJ (Fig. 3Bc).
I-SceI-induced accNHEJ at the human HPRT locus
HPRT+ HT1080 cells were electroporated with pLB-puro and
clones were selected in 6TG and puromycin (Fig. 3Ba). From a
total of 20 million cells, 12 clones were obtained, consistent
with the low un-induced targeting frequencies in HT1080 cells
(47). One such clone (clone 5.2) was then electroporated with
I-SceI expression plasmid, or mock transfected, and only the for-
mer transfection generated HATR clones (not shown). Southern
analyses of a pool of >200 HATR colonies (clone 5.2P), two HATR
clones (clones 5.2.1 and 5.2.2; both sensitive to puromycin) and
parental clone 5.2 confirmed the presence of the I-SceI site in
exon 6 (Supplementary Material, Fig. S2A and B). To estimate
the frequency of accNHEJ, multiple lipofections of clone 5.2
with I-SceI expression plasmid were carried out and the fre-
quency of resulting HATR colonies was measured at 4.1% [stand-
ard deviation (SD): 1.15; n = 4]. Among these HATR colonies, 4.4%
(SD: 0.59; n = 4) remained PuroR, presumably due to reintegration
of the excised puromycin cassette at randomgenomic loci. These
results support the use of clone 5.2, or equivalent clones, in as-
says for accNHEJ as outlined (Fig. 3Bb). Though highly specific,
this assay detects only accNHEJ events between two DSBs, ex-
cluding the probably more frequent accNHEJ events involving
only one DSB (see Discussion).
I-SceI-induced mutNHEJ at the human HPRT locus
When transfected with an I-SceI expression plasmid, clone 5.2.1
(HP-I-RT+) generated 6TGR colonies, as expected for DSBR by
mutNHEJ resulting in indels (Fig. 4A). In standard lipofection pro-
tocols, 6TGR colonies were generated at frequencies of 1.5% (SD:
0.96, n = 8), three to four orders of magnitude higher than the
frequency of spontaneous 6TG resistance (Fig. 4B and C). To char-
acterize the expected indels, the exon 6 regions of 28 individual
6TGR clones were amplified and sequenced (Fig. 4A and D–F).
The majority (17/28) had small indels involving <14 nt, all but
two of which were simple deletions. The rest involved larger
deletions (3/28), insertions (6/28) or both (2/28). These results
support the use of the I-SceI-sensitive HPRT+ allele in clone 5.2.1
(or equivalent clones), in assays to detect DSB-induciblemutNHEJ.
Figure 3. Generating and using I-SceI-sensitive hHPRT alleles. (A) Structure of
parental and I-SceI-sensitive hHPRT alleles. Numbered black boxes represent
exons. Partial nucleotide and amino-acid sequences for exon 6 are shown for the
WT allele and for alleles modified to carry an I-SceI site (boxed), with (hHP-I*-RT)
or without (hHP-I-RT) an adjacent stop codon. Altered residues are shown in bold.
An AseI site in hHP-I*-RT is underlined. (B) Strategy for generating I-SceI-sensitive
alleles and using them for accNHEJ and mutNHEJ assays. (a) Disruption of exon 6
by GT with pLB-puro. (b) Basis of accNHEJ assay. An I-SceI-induced DSB repaired
by accNHEJ generates a functional I-SceI-sensitive allele. The frequency of
resulting HATR colonies measures accNHEJ. (c) Basis of mutNHEJ assay. An I-SceI-
induced DSB is repaired by mutNHEJ to generate an indel (hatched box). The
frequency of resulting 6TGR colonies measures mutNHEJ. Exon 6 (black box) and
adjacent intronic DNA of the chromosomal HPRT locus (long lines) are shown.
Targeting construct pLB-puro is shown with its puromycin-resistance cassette
(PURO, white box) and its 2.7 and 3.1 kb arms aligned with homologous
chromosomal regions (dotted lines) to allow HR (X). Sites for I-SceI (I) are shown.
Alleles are labelled with their names (right) and the names of representative host
cell lines (left). Resistance (✓) or sensitivity (✗) to key selective agents is indicated.
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I-SceI-induced correction of the human HPRT gene
As a model for nuclease-induced gene correction by HR (gc/HR),
we used a GT plasmid (pJB1-Ase) to generate clones with an in-
active HPRT allele (HP-I*-RT−) in which the silent I-SceI site in
exon 6 has an adjacent stop codon and AseI site (Figs 3A and
5Aa; Supplementary Material, Fig. S2C). Ten million HPRT+ cells
electroporated with pJB1-Ase generated five 6TGR colonies, four
of which (clones 3A, 3B, 10B1 and 10B3) had AseI fragments indi-
cative of the desired modification (Supplementary Material,
Fig. S2C). Southern analyses confirmed the presence of an I-SceI
site in exon 6 in each of three clones tested (3B, 10B1 and 10B3;
Supplementary Material, Fig. S2A). Clone 3B was then used for
Figure 4.Assays for I-SceI-inducedmutNHEJ andDNA sequence analyses of resulting indels inHPRTexon 6. (A)HPRTexon 6 in clone 5.2.1 is cleaved by I-SceI and repaired by
mutNHEJ to generate 6TGR clones carrying exon 6 indels (hatched); these are amplifiedwith flanking primers (short arrows) and sequenced (dashed arrow). (B) Frequency
of 6TGR clones generated from clone 5.2.1 lipofected with I-SceI expression plasmid or a vector control (mean and SD for six experiments are shown). Transfection was by
lipofectamine 2000, but similar resultswere obtainedwith Fugene. (C) Example of 6TGR colonies forming in the experiment in B. Petri dishes (10 cmdiameter) were seeded
with 105 cells before selecting in 6TG. (D) Part of the exon 6 DNA sequence in clone 5.2.1 is shown alignedwith encoded amino acids 142–152. The recognition site for I-SceI
is shown (bold) with positions of staggered nicks it makes (arrows) and un-cleaved phosphodiester bonds opposite each nick (hyphens). (E) Small indels. Coding strand
DNA sequences of 11 indels identified in seventeen 6TGR clones are shown with deleted and inserted residues highlighted in grey and black, respectively. The number of
clones for each indel is shown (n). Positions of indels are summarizedwith residues numbered relative to the coding strand nick.Micro-homologies likely to havemediated
deletion formation are underlined. Indel types: small and large deletions (SD, LD), or insertions (SI, LI). The predicted effects on protein coding are categorized as frame-
shifts (FS) or in-framedeletions (Δ). (F) Large indels. Sequences of 11 junction regions are shownwithDNA represented as in (B). Except for insertions, upper and lower case
letters represent exon 6 and intronic residues, respectively. Type and position numbers of indels are summarized as in (B). The origin of the inserted DNA is indicated. na,
no sequence available.
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gc/HR assays in which a repair construct (pJB2) was co-lipofected
with an I-SceI expression plasmid (or vector control), followed by
selection in HAT (Fig. 5Ab). After normalizing for plating efficien-
cies, the frequency of HATR colonies, and therefore gc/HR, was
found to be 0.16% (SD: 0.07; n = 6). Representative results for one
experiment are shown in Figure 5B. Further experiments (not
shown) confirmed that gc/HR requires co-transfected repair tem-
plate and that clones 3A and 10B1 behaved similarly to clone 3B.
These results support the use of the I-SceI-sensitive HPRT− allele
in clone 3B (or equivalent clones) in assays to detect DSB-indu-
cible gene correction and show that this is ∼10-fold less efficient
than repair of the same DSB by mutNHEJ.
Cell cycle-specific control of I-SceI-induced DSBR
Cell cycle studies typically rely on synchronization methods that
use drugs or serum starvation to arrest the cycle or physical sep-
aration by centrifugal elutriation or flow cytometric cell sorting.
Problems with these methods include the induction of cell stress
responses, variable sensitivities to serum starvation and the
need for expensive equipment with experienced operators (48).
We reasoned that, in the context of DSBR, the expression of nu-
cleases in a cell cycle-restricted fashion might provide a simple
alternative to such approaches. We, therefore, used Fucci tech-
nology (49) to develop plasmids encoding fluorescent I-SceI
derivatives that accumulate preferentially in G1/S (pSce-Cy-G1)
or S/G2 (pSce-Cy-G2). These encode I-SceI fused to AmCyan fluor-
escent protein (Cy) with C-terminal peptides derived, respective-
ly, from Cdt1 and Geminin (Fig. 6A; Supplementary Material,
Table S2). Analyses of DNA content in transiently transfected
AmCyan-positive (AmCyan+) cells confirmed that pSce-Cy-G1-
and pSce-Cy-G2-transfected cells were enriched in G1/S and
S/G2, respectively (Fig. 6B). To investigatewhether the constructs
have differential effects on previously established DSBR assays,
theywere transfected into cells stably transfectedwith the repor-
ters DR-GFP (13) and SA-GFP (16) for measuring, respectively, I-
SceI-inducible intrachromosomal HR and SSA (Fig. 6C). The DR-
GFP signal was ∼2-fold greater in cells expressing pSce-Cy-G2
than in cells expressing pSce-Cy-G1, consistent with the known
restriction of HR to S/G2. Conversely, the SA-GFP signal was ∼2-
fold greater in cells expressing pSce-Cy-G1 than in cells expres-
sing pSce-Cy-G2, consistent with studies suggesting that SSA
does not occur in G2 (50) and that resection can occur in G1
(51). These results suggested that our Fucci I-SceI constructs are
able to introduce DSBs in restricted phases of the cell cycle, as in-
tended. To assess how the Fucci I-SceI constructs affect mutNHEJ
and gc/HR at the hHPRT locus, we then transfected them into
clones 5.2.1 (HP-I-RT+) and 3B (HP-I*-RT−), respectively (Fig. 6D).
Similar to the DR-GFP assays, pSce-Cy-G2 induced gc/HR with
∼3-fold greater efficiency than pSce-Cy-G1. Conversely, pSce-
Cy-G2 induced mutNHEJ ∼3-fold less efficiently than pSce-Cy-
G1 suggesting that, although NHEJ operates throughout the cell
cycle, mutNHEJ occurs preferentially in G1/S in HT1080 cells. To-
gether, these observations support the use of our modified I-SceI
expression plasmids for studying the influence of cell cycle on
any DSB-inducible cell response.
Comparison of Cas9- and I-SceI-induced DSBR at HPRT
exon 6
To develop HPRT-based DSBR assays that do not rely on introdu-
cing an I-SceI site into the genome, and to compare I-SceI and
CRISPR-induced DSBR pathways, we designed four exon 6-specif-
ic guide RNAs for the Cas9 nuclease of Streptococcus pyogenes: two
(gRNA-1 and -2) targeting wild-type HPRT alleles and two (gRNA-
3 and -4) targeting I-SceI-sensitiveHPRTalleles (Fig. 7A). To test for
Cas9-induced mutNHEJ, wild-type cells or I-SceI-sensitive HPRT+
cells (clone 5.2.1) were co-transfected with expression plasmids
for Cas9 and each of the four gRNAs, and 6TGR colonies were se-
lected. For a positive control, the I-SceI expression plasmid was
transfected in parallel. The results (Fig. 7B, Table 2) clearly
showed the expected gRNA targeting preferences. Thus, high fre-
quencies of 6TGR colonies (up to 3.6-fold higher those induced by
I-SceI in clone 5.2.1) were induced by gRNA-1 and -2 in wild-type
cells, and by gRNA-3 and -4 in clone 5.2.1 cells. Conversely, no
6TGR colonies were generated in wild-type cells by gRNA-1 or in
clone 5.2.1 by gRNA-3 or -4. These results indicate stringent al-
lele-specific exon6mutagenesis directed bygRNAs 1, 3 and4.Mu-
tagenesis directed by gRNA-2, though highly efficient in clone
5.2.1, was also appreciable in parental cells. This most likely re-
flects the fact that gRNA-2 has only one mismatch to the wild-
type allele and so can direct Cas9-mediated cleavage, albeit less
efficiently than at the I-SceI-sensitive allele.
We sequenced the exon 6 region in a range of 6TGR clones gen-
erated in the experiment of Figure 7B and in similar experiments
(Supplementary Material, Fig. S3). For both Cas9 and I-SceI, indels
occurred at the expected sites. We classified these indels, and
those of Figure 4, as small or large deletions or insertions, or
other more complex events. We noted a striking difference in
Figure 5.Generating and using I-SceI-sensitive hHPRT+ alleles for gc/HR assays. (A)
DNA is represented as in Figure 3. (a) HR between a wt HPRT allele and the
targeting construct pJB1-AseI was used to introduce an I-SceI site and adjacent
stop codon (*) into exon 6. The resulting cells (e.g. clone 3B) were selected in
6TG. (b) Basis of assays for gene correction by HR (gc/HR). Clone 3B cells are
transfected with a repair template (pJB2) and nuclease expression plasmid(s).
HR with transfected pJB2 regenerates a functional exon 6 and the frequency of
resulting HATR colonies measures gc/HR. (B) Example of one experiment to
estimate gc/HR frequencies. Clone 3B cells were co-transfected with pJB2 and
either vector DNA (Transfection 1) or I-SceI expression plasmid (Transfection 2),
and the indicated relative numbers (Rel. No.) of cells were placed in petri dishes
to select in HAT for gene correction events or to determine plating efficiencies
(no selection). Colonies appearing after ∼10 days were counted and used to
estimate gc/HR frequencies of <0.00016% (Transfection 1) and 0.17%
(Transfection 2).
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the frequency of small insertion mutations generated by I-SceI
and Cas9 (Fig. 7C): small insertions represented the least abun-
dant class of I-SceI-generated mutations (1/38; 2.6%), but the
most abundant class of Cas9-generatedmutations (20/58; 34.5%).
Finally, we tested gRNA-1, -3 and -4 for their ability to support
Cas9-induced gene correction in I-SceI-sensitive HPRT− cells
(clone 3B). As expected, gRNA-3 and -4, but not gRNA-1, sup-
ported Cas9-mediated gene correction (Table 3). Also as ex-
pected, detectable levels of correction induced by gRNA3/Cas9
depended, as for I-SceI, on template co-transfection. Interesting-
ly, Cas9-induced gene correction was ∼7-fold less efficient than
I-SceI-induced correction. This contrasted with Cas9-induced
mutNHEJ that was on average 1.7-fold more efficient than
I-SceI-induced mutNHEJ (Table 2). Together with the differences
in mutNHEJ mutation signatures (Fig. 7C), these results suggest
that Cas9- and I-SceI-generated DSBs are processed differently
during DSB repair.
Discussion
In this study, we have developed a system for measuring the re-
pair of I-SceI- or Cas9-induced DSBs by three different mechan-
isms, all at the same site in the endogenous HPRT gene. We
have used these assays to estimate the absolute and relative
frequencies of the different DSBR mechanisms, to discover that
I-SceI and Cas9 induce distinct mutNHEJ mutation signatures
and mutNHEJ:GT ratios, and to validate novel I-SceI derivatives
for studying DSBR in different cell cycle phases. In addition, we
have used an I-SceI-sensitive HPRT minigene to compare the
efficiencies of different DNA repair templates.
Advantages and limitations of DSBR assays using the
endogenous HPRT locus
A key attraction of the endogenous HPRT assay system is its abil-
ity to measure three DSBR pathways (GT, mutNHEJ and accNHEJ)
at the same site. As outlined in the Introduction, the comparison
of multiple DSBR pathways at a single locus is preferable to the
comparison of single pathways at multiple loci. This is because
the interactions between a reporter and its chromosomal envir-
onment, and any associated effects on DSBR, vary unpredictably
between loci. Several studies have compared two DSBR pathways
at a single locus but, to our knowledge, detection of three path-
ways at a single locus has been described only once, for a differ-
ent combination of pathways (GT,mutNHEJ and SSA) using a TLR
construct (26).
For mutNHEJ, the endogenous HPRT system has the advan-
tage of being able to detect a full spectrum of indels. Thus, by
Figure 6. Development and use of cell cycle-specific I-SceI. (A) Schematic representation of I-SceI expression plasmids. Ellipse, cytomegaloviral promoter; black bar,
haemagglutinin tag. (B) Cell cycle profiles of cells lipofected with the indicated plasmids. Cells were HT1080-WT (left), HT1080-AS5 (Supplementary Material, Table S1;
centre) and HeLa (right). (C) Differential effects of cell cycle-restricted I-SceI on reporters for HR and SSA. The indicated plasmids were transfected into cells (HT-DR-
GFP-8 or HT-SSA-GFP; Supplementary Material, Table S1) carrying GFP-based reporters for a HR or SSA. The percentage of AmCyan+ cells that were GFP+ is shown. (D)
Differential effects of cell cycle-restricted I-SceI on mutNHEJ and gene correction at the HPRT locus. Assays based on clone 5.2.1 (mutNHEJ) or clone 3B (gene
correction) were used with the indicated I-SceI expression plasmids. Results were normalized to the amount of AmCyan expression. Mean and SDs for three or more
assays are presented with significant differences marked (*P < 0.05; Student’s t-test).
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cleaving an essential HPRT coding region, we detected single nu-
cleotide indels and in-frame deletions of just a single codon
(Fig. 4D). Furthermore, we detected indels of over 600 bp
(Fig. 4F) closer in size the HPRT mutations commonly detected
after ionizing irradiation (43). Most mutNHEJ assays use gain-
of-function reporters whose reading frame must be restored so
Figure 7. Cas9-induced HPRTmutagenesis. (A) Design of exon 6-targeted gRNAs. Part of the exon 6 sequence inWT cells or clone 5.2.1 is shown. The I-SceI site is boxed with
non-WT residues shown in bold and the cleavage site indicated (staggered arrows). Target-specific regions of gRNAs are shown, alignedwith their target. For each gRNA, the
predicted Cas9 cleavage site is indicated by an arrow, 3 nt upstream of the protospacer-adjacent motif (underlined). (B) Stained petri dishes after selection of transfected
HT1080 or clone 5.2.1 cells (106 cells per dish) in 6TG. Cells were lipofected with DNA encoding no nuclease (column 1), Cas9 and the indicated gRNA (columns 2–5), or
I-SceI (column 6). Cells from the same transfection shown in (B) were plated at lower dilutions and selected in 6TG and used to determine frequencies (Materials and
Methods; Table 3, Experiment 1). (C) Relative proportions of different classes of I-SceI- or Cas9-inducedmutations (data from Fig. 4D and E; Supplementary Material, Fig. S3).
Table 2. Relative frequencies of HPRT mutagenesis by Cas9 and I-SceIa
Expt. Host cells HPRT genotype Nuclease
None gRNA1/Cas9 gRNA2/Cas9 gRNA3/Cas9 gRNA4/Cas9 I-SceI
1 WT HPRT+ UD 1.5 1.7 UD UD UD
1 5.2.1 HP-I-RT+ UD UD 0.05 1 3.6 1
2 5.2.1 HP-I-RT+ nt UD nt 1.3 nt 1
3 5.2.1 HP-I-RT+ nt nt nt 0.5 1.4 1
4 WT HPRT+ UD 2.6 nt UD UD UD
4 5.2.1 HP-I-RT+ UD UD UD 1.6 2.9 1
UD, undetectable (<10−5); nt, not tested.
aFigures show the frequencies of 6TGR colonies generated by the indicated nucleases relative to frequencies generated by I-SceI.
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that, at best, only one-third of all possible indels can be detected.
Furthermore, many large indels are expected to prevent reporter
cassette activation, for example, by deleting into its promoter or
coding sequences, or by the inserting exogenous sequences that
impair expression. In a loss-of-functionmutNHEJ assay based on
the endogenous thymidine kinase gene, I-SceI cleaved a non-
coding region and so was unable to detect all indels (52).
Like other reporters, the endogenous HPRT system requires
two I-SceI sites to detect accNHEJ, but it is unusually selective be-
cause, as shown in ourmutNHEJ assays, even the smallest indels
are incompatible with HAT resistance. This contrasts with other
reporter systems where small indels were compatible with re-
porter gene expression, so that DNA sequence analyses were re-
quired to distinguish accNHEJ from mutNHEJ (10,17–20). In
common with most other accNHEJ reporters, however, our
HPRT-based assay underestimates the true level of accNHEJ, part-
ly because multiple cycles of accNHEJ and re-cleavage increase
the chance that DSBR will ultimately occur by mutNHEJ. This
issue was addressed in another study by use of an exogenous
reporter in which accNHEJ of two mutant I-SceI generates a site
resistant to further cleavage (10), a feature that could readily be
incorporated into the HPRT assay. Nevertheless, another cause
for accNHEJ underestimation, lack of reporter activation by ac-
cNHEJ at only one of the two I-SceI sites, remains to be addressed
in any accNHEJ assay.
Assaying for GT at the cleavedHPRT locus is, like themutNHEJ
and accNHEJ assays, highly selective. HPRT can, therefore, report
for these different DSBR mechanisms without the need for DNA
sequencing of multiple clones, an advantage shared with TLRs.
Although selection and scoring of drug-resistant colonies is
less convenient than analyses of fluorescent reporters, the
HPRT system does not require a multicolour flow cytometer and
conveniently delivers clones ready for any further analyses that
might be required. Furthermore, the HPRT assay is highly sensi-
tive, easily capable of unambiguously detecting one event
among a million or more cells.
The fact that HPRT is an endogenous housekeeping gene also
has attractions. First, use of HPRT avoids the need to integrate an
exogenous reporter into the genome and to demonstrate single
copy integration. Indeed, measurements of Cas9-induced mutN-
HEJ can be carried out without any preparatory modifications of
the host cells. Although HPRT modifications, such as the intro-
duction of an I-SceI site, are required for measuring accNHEJ
and GT, the reagents and selection steps we have described
should be applicable in most cell lines. Second, as outlined
above, the fixed genomic location of HPRT is an advantage if
one wishes to compare DSBR in different cell types. Similarly,
the conservation of HPRT allows for well-controlled comparisons
of DSBR between cells from different species. Although afixed lo-
cation precludes studies of chromosome position effects on
DSBR, for this purpose, an HPRT minigene or bacterial artificial
chromosome carrying thewholeHPRT gene can be ectopically in-
tegrated, with the endogenous locus serving as a reference.
Third, the endogenous HPRT system allows DSBR to be studied
at a natural gene with features such as multiple introns and re-
peat sequences intact and unmodified by exogenous sequences
that may affect DSBR.
Relative frequencies of different DSBR pathways
Our estimated efficiencies of I-SceI-induced mutNHEJ and GT the
endogenous HPRT locus in HT1080 (human fibrosarcoma) cells
were 1.5 and 0.16%, respectively, giving a mutNHEJ:GT ratio of
∼9:1. In a previous study, where different chromosome positions
of the mutNHEJ and GT reporters were taken into account, the
I-SceI-induced mutNHEJ:GT ratio was estimated at random loci
in HCA-2 (human colon cancer) cells to be 6:1 (23). In another
study, where chromosomal position effects were avoided by
use of a TLR, the average mutNHEJ:GT ratios were estimated at
transcribed and untranscribed loci in HEK293 (human embryonic
kidney) cells to be 4:1 and 25:1, respectively (26). For comparison
with our estimate, these estimates must be increased 3-fold (be-
cause their mutNHEJ reporters detect only in-frame indels), to
give ratios of 18:1, 12:1 and 75:1, respectively. Thus, despite the
differences in variables such as cell type and DNA deliverymeth-
od, our estimate of 9:1 is in good agreement with the value of 12:1
corresponding to a pool of transcribed loci derived from the study
of Kuhar et al. This suggests that the endogenous HPRT locus is
representative of an average transcribed locus, when measuring
DSBR.
Our estimated efficiencies of I-SceI-induced accNHEJ and
mutNHEJ at the HPRT locus in HT1080 cells were 4.1 and 1.5%, re-
spectively, giving an accNHEJ:mutNHEJ ratio of∼3:1. As discussed
above, although our accNHEJ andmutNHEJ assays are particular-
ly specific, they are also likely, in common with other assays, to
underestimate this ratio, partly because of re-cleavage of accur-
ately repaired DSBs. Thus, our estimate is a robust only as a
minimum estimate; true values require further investigation
and are likely to be much higher. Perhaps the best estimate to
date (∼50:1) used an accNHEJ substrate that cannot be re-cleaved
by I-SceI after accNHEJ (10). Further estimates are required that
not only compensate for re-cleavage by nuclease but also detect
accNHEJ at a single DSB.
Differences between I-SceI- and Cas9-induced DSBR
It was surprising that, compared with I-SceI, Cas9 induced higher
frequencies of mutNHEJ and lower frequencies of GT, even
though both nucleases targeted the same regions in HPRT exon
6. It was also striking that Cas9, unlike I-SceI, had a marked pro-
pensity to generate small (mostly 1 nt) insertions. A high propor-
tion of single nucleotide insertions among Cas9-induced indels
has been noted previously (53,54), but its significance is unclear.
It is possible that these differences between Cas9- and I-SceI-in-
duced DSBR reflect the different DNA ends they generate. Thus,
the recessed 5′ ends generated by I-SceI may be more prone
than blunt Cas9-generated ends to undergo further 5′ end-resec-
tion, favouring RAD51 filament formation and GT at the expense
of mutNHEJ. This interpretation is also consistent with recent
data showing that a customized nuclease that generates protrud-
ing 5′ ends stimulated GT less efficiently than cleavage of the
same reporter by I-SceI (26). The high proportion of single base in-
sertions among Cas9-induced indels is accompanied by a de-
crease in the proportion of small deletions (Fig. 7C). This could
be explained if blunt ends are less susceptible to nuclease
Table 3. Frequencies of gc/HR induced by different HPRT-targeted
nucleasesa








Template − + + − + +
Experiment 1 UD 0.093 UD UD 0.013 nt
Experiment 2 nt 0.12 nt nt 0.016 0.019
UD, undetectable; nt, not tested.
aFigures show % of colony forming units that became HATR after lipofection of
clone 3B with the indicated nucleases with or without repair template (pJB2).
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digestion than 3′-overhangs, and so more susceptible to nucleo-
tide addition. Consistent with this, chromosomal translocations
induced by wild-type Cas9 involve deletions less frequently than
natural translocations or translocations induced by paired Cas9
nickases (55). Further investigations of how DSBR pathways are
affected by different nuclease and DSB end-structures will be
valuable for elucidating natural mutagenesis and optimizing
genome engineering methods.
The ease with which CRISPRs can be developed will facilitate
further analyses of DSBR at various regions in the HPRT locus.
The ability to place a silent I-SceI site in exon 6will nevertheless re-
main a valuable option for studies of DSBR usingHPRT as a report-
er. For example, it will allow comparisons of DSBR at the HPRT
locus in different species using a single defined nuclease, or stud-
ies of the influence of effector proteins, targeted to the HPRT locus
by fusion to a nuclease-inactive Cas9, on I-SceI-induced DSBR.
Cell cycle regulated I-SceI
Fusion of Geminin- or Cdt1-derived peptides to AmCyan-tagged
I-SceI allowed us to induce DSBs preferentially in S/G2 and G1/S,
respectively. This approach offers a relatively simple and non-in-
vasive way to study how any DSB-induced cellular response var-
ies with cell cycle and adds to previous modifications of I-SceI
designed to extend its versatility as a tool in the study of DSBR
(24,56,57). So far, we have used our approach to demonstrate
cell cycle regulation of intrachromosomal HR, SSA, gc/HR and
mutNHEJ, but it will be interesting to extend this to other DSBR
pathways, including accNHEJ. It should be noted that DSBR as-
says preferentially activated by a phase-specific I-SceI, while indi-
cative of phase-specific DSBR, do not always indicate that DSBR
occurs in that phase. In cells with defects in NHEJ and cell cycle
checkpoints, for example, DNA damage inflicted in one cell
cycle phase may be repaired in a subsequent phase (58).
A similar approach to that describedheremay be applicable to
CRISPRs with potential implications for genome engineering. For
example, the use of S/G2-restricted nucleases may provide a way
to enhance the proportion of any desired HR-mediated genomic
modifications at the expense of unwanted NHEJ-mediated
events. In our study, AmCyan+ cells were enriched in G1/S or
G2/S phases, but the absolute numbers of AmCyan+ phase-en-
riched cells were limited. It will, therefore, be important to opti-
mize levels of I-SceI-fusion protein expression if these reagents
are to be fully exploited.
Use of a HPRT minigene reporter
Although our initial experiments involved an ectopic mouse
HP-I*-RT minigene and were not used to measure absolute fre-
quencies of gene correction, they did generate several interesting
results concerning the mechanisms of GT efficiencies using
different templates. First, we measured similar frequencies of
DSB-induced gene correction for sense and antisense single-
stranded oligonucleotides (ssOs). This could not have been
predicted from a similar result for un-induced ssO-directedmod-
ifications (59), which are thought to involve ssO annealing at
replication forks (60,61) rather than at resected DSBs, as is envi-
saged for nuclease-inducedDSBR (62). Our results, therefore, sug-
gest that resection and oligonucleotide annealing on each side
of the DSB are equally efficient. Second, the higher efficiency of
ssO- relative to dsO-templated correction suggests that ssO an-
nealing at resected DSB ends is preferred over invasion of the
dsO by the resected ends, as is envisaged for long double-
stranded templates (see 63). Third, the >20-fold increase in GT
on increasing the ds template length from 60 to ∼1700 bp is of
note. Un-induced GT efficiencies increase exponentially with
template length (64), probably because the chance that a random
chromosome DSB occurs within the homology region increases
with template length. For nuclease-inducedGT, however, this ex-
planation does not apply. It may be, therefore, that increasing
homology favours homology searching and/or strand invasion,
or that long double-stranded templates are less susceptible to
degradation than double-stranded oligonucleotides. Fourth, the
greater effectiveness of wild-type templates compared with
equivalent templates with I-SceI sites was observed for both
double- and single-stranded templates. This suggests that re-
cleavage of the repaired chromosome by I-SceI ismore of a barrier
to gene correction than cleavage by I-SceI of double-stranded
templates prior to HR. Finally, the greater efficiency of GT with
long double-stranded templates than with oligonucleotides con-
trasts with other studies where ssOs supported nuclease-
induced gene modifications with similar or greater efficiencies
than plasmid templates (46,65,66). The reason for this difference
is unclear, but it may reflect differences in optimal experimental
conditions required for different loci and cell types. For example,
although our oligonucleotide concentrations were similar to
those used by others (46), they were not necessarily optimal. In-
deed, increasing oligonucleotide concentrations enhanced cor-
rection frequencies up to 4-fold (SupplementaryMaterial, Fig. S3).
In summary, we have demonstrated the versatility of using
HPRT to investigate nuclease-induced DSBR at an endogenous
locus. Although nucleases have previously been used to induce
DSBR at endogenous selectable genes (52,67–71), our study
uniquely combines the analysis of three different types of DSBR
at an endogenous locus, the use of I-SceI to cleave a functional
exon (allowing a fuller range of DSBR events to be selected) and
the comparison of I-SceI- and Cas9-induced DSBR. The use of an
exogenous HPRTminigene to study gene correction and of modi-
fied I-SceI to study cell cycle-specific DSBR adds further novelty
and utility to this study. These systems will be applicable in a
wide range of investigations into DSBR.
Materials and Methods
Cell culture and transfection
HT1080 fibrosarcoma cells and derivatives and HeLa cells were
grown as previously described (72). Supplementary Material,
Table S1 summarizes key properties of various HT1080 deriva-
tives used. For electroporations, a Gene Pulser (BioRad) was
used as previously described (72). For lipofections, lipofectamine
2000 (LF; Life Technologies) or Fugene 6 (Promega) was used ac-
cording to the manufacturers’ instructions, in multiwall well for-
mats with, per cm2, 0.5–1 million cells, a total of 0.4 µg (LF) or
0.6 µg (Fugene) DNA and 1 µl (LF) or 1.8 µl (Fugene) cationic lipid
reagent. Under these conditions, 70–90%ofHT1080 cells lipofected
with a green fluorescent protein (GFP) expression plasmid became
GFP+ 24–48 h post-lipofection. For nucleofection, an Amaxa
Nucleofector I (Lonza) was used according to the manufacturer’s
recommendations (program L005, transfection solution T).
Drug selections and colony counts
To select for stably transfected/modified clones or populations,
the following drug selections were used: hygromycin B (Invitro-
gen; 100 µg/ml), zeocin (Invivogen 200 µg/ml), puromycin (Invi-
vogen; 0.4 µg/ml), HAT supplement (Life technologies) and 6TG
(Sigma; 15 µg/ml). After transfection, but prior to selecting in
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6TG, cells were maintained without selection for 5 days, passa-
ging as necessary. Other selective agents were added to trans-
fected cells 48 h post-transfection. Because 6TG and HAT
selection are initiated 48 h or more after transfection, by which
time most DSB is complete (14), any influence of HAT or 6TG on
DSBR is minimized. To determine frequencies of HATR or 6TGR
cells, colonies were selected in 9 cm diameter dishes over a
range of cell dilutions. To determine plating efficiencies, a high
dilution was plated without selection. Colonies were stained
with crystal violet as described (72). Dilutions generating appre-
ciable but limited numbers of HATR or 6TGR colonies (e.g. 50–
300) were chosen for colony counting. To allow for plating effi-
ciency variations, the number of selected colonies in a given
dish was divided by the number of colony forming units in that
dish, as calculated from the number of colonies that formed
without selection at a known dilution of the same culture.
DNA manipulations and plasmids
Key features of the plasmids used in this study are summarized
in SupplementaryMaterial, Table S2. Standard recombinant DNA
methods were used for plasmid construction. Correct assembly
was confirmed by restriction enzyme mapping and/or DNA se-
quencing. Details of construction and/or plasmidmaps are avail-
able on request. The following kind gifts were made—mHPRT
minigene vector pBT/PGK-HPRT (73): David Melton (Edinburgh
University); I-SceI expression plasmid pCMV3xnls-I-SceI (74) and
reporter constructs DR-GFP (13) and SA-GFP (16): Maria Jasin (Me-
morial Sloan-Kettering Cancer Center) and expression constructs
for gRNA (Addgene 41824) and Cas9 (Addgene 41815): George
Church (Harvard Medical School, via Addgene). Cloning of
gRNA into 41824 was as described (75).
Oligonucleotides, polymerase chain reaction and DNA
sequencing
Oligonucleotides used asmHP-I*-RT repair templates are described
in Supplementary Material, Table S3. To characterize indels,
hHPRT exon 6 regions were amplified as follows. A 1433 bp region
was amplifiedwithprimers P1 (5′-AGGGAACCCTTCTGTGTGTG-3′)
and P2 (5′-GGACAATTCCCTATGCCTCA-3′) under the following
conditions: 120 min at 94°C, then 30 cycles of 10 min at 94°C,
30min at 60°C, 80 min at 72°C, then 120 min at 72°C. Alternatively,
a 507 bp region was amplified with primers P3 (5′-GGCATTCT
TACTGCTTGCTG-3′) and P4 (5′-TCTGCCATGCTATTCAGGAC-3′)
under same conditions except with 30 min at 72°C instead of
80 min. Polymerase chain reaction products were purified and
sequenced with primer P3 or P4.
Southern analyses
Use of genomic DNA (preparation, digestion, electrophoresis and
transfer to nylonmembranes) and probes (32P-labelling and hybri-
dizations to membranes) were essentially as described previously
(72). The hHPRTprobewas a 654 bpXbaI–BamH1 fragment of hHPRT
genomic DNA including exon 5 and part of intron 5. The puro-
mycin probe was a 1.2 kb XbaI fragment from pBL-Puro/R (76).
Flow cytometry
Measurements of GFP fluorescence aloneweremade in a Facscali-
bur (Beckton Dickinson; 488 nm laser). Measurements of AmCyan
fluorescence in combination with propidium iodide (PI) or GFP
fluorescence were made in an LSRII flow cytometer (Becton Dick-
inson; 405 and 488 nm lasers). To determine cell cycle profiles,
cells were washed in phosphate buffered saline A (PBSA) and
fixedbydrop-wise additionof 500 µl cold (−20°C) 70% (v/v) ethanol,
with vortexing, and stored at −20°C. Fixed cells were washed in
PBSA at 40°C and incubated in RNaseA (10 µl; 1 mg/ml) for
30min on ice, then resuspended in PI (200 µl, 50 µg/ml). For trans-
fected cells, PIfluorescencewasmeasured inpopulations gated for
AmCyan fluorescence.
mHPRT-based gene correction assays
Clone 2.1 cells were grown with (I-SceI off ) or without (I-SceI on)
tetracycline (Sigma; 1 µg/ml) for 48 h prior to nucleofection. Un-
less stated otherwise, each nucleofection used 250 000 cells with
5 µg of oligonucleotide or plasmid template. After nucleofection,
cells were passaged for 5 days, with or without tetracycline. The
entire population was then selected in HAT for 10–14 days and
the resulting HATR colonies were counted.
hHPRT-based DSBR assays
To measure I-SceI-induced accNHEJ, clone 5.2 cells were lipo-
fected with pCMV3xnls-I-SceI and the frequency of resulting
HATR colonies was determined. To measure I-SceI-induced
mutNHEJ, clone 5.2.1 was lipofected with pCMV3xnls-I-SceI and
the frequency of resulting 6TGR colonies was determined. The
same protocol was used to measure CRISPR-induced mutNHEJ
in clone 5.2.1 cell or wt HT1080 cells, except that equal weights
of gRNA- and Cas9-expression plasmids were co-transfected.
To measure I-SceI- or CRISPR-induced gc/HR, clone 3B was lipo-
fected with equal amounts of pCMV3xnls-I-SceI and repair tem-
plate (pJB2) or equal amounts of plasmids encoding gRNA, Cas9
and I-SceI. The frequency of resulting HATR colonies was then
determined.
Assays for I-SceI-AmCyan-induced DSBR
For mutNHEJ and gc/HR assays induced by I-SceI-AmCyan fu-
sions, part of the transfected culturewas analysed 48 h post-lipo-
fection to determine the proportion of AmCyan+ cells (typically
<1%). Frequencies of mutNHEJ and gc/HR were then divided by
their corresponding fraction of AmCyan+ cells. Cell lines HT-
DRGFP-8 and HT-SAGFP-6 lipofected with I-SceI-AmCyan expres-
sion plasmids were analysed flow cytometrically 48 h post-
lipofection. After gating on 50 000–100 000 AmCyan-expressing
cells, the proportion that also expressed GFP was measured.
Supplementary Material
Supplementary Material is available at HMG online.
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